Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL
Status:
Not yet recruiting
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
A Czech Lymphoma Study Group, phase II, open-label, study of polatuzumab-vedotin in
combination with bendamustine and rituximab for patients with mantle cell lymphoma, who
relapse after previous therapy with Bruton tyrosine kinase inhibitor